Ownership
Private
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Visolis General Information

Visolis has successfully scaled its technology to ton-level manufacturing, delivered on-spec products to early customers, secured multi-million-dollar joint development agreements, achieved multi-millions in annual revenue, and is preparing to launch its first large-scale commercial facility in 2025—a 40X scale-up from current operations. The company’s platform produces sustainable aviation fuel (SAF), synthetic rubber precursors like bio-isoprene, non-toxic solvents, synthetic latexes, and other specialty/commodity chemicals with lower cost and carbon footprint than traditional processes. Visolis’ SAF offers higher energy density than many alternatives. Its process uses waste biomass or CO₂ as feedstock via engineered microbes followed by chemical catalysis for efficient production at scale. The company recently received a $2.25M U.S. Department of Defense award for domestic manufacturing expansion. No clinical results are relevant.

Contact Information

Website
Primary Industry
Non-Drug Biotech
Corporate Office
Hayward, California
United States

Drug Pipeline

No pipeline data available

For full access to Visolis's pipeline data

Book a demo

Key Partnerships

Ginkgo Bioworks

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Visolis Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Visolis's complete valuation and funding history, request access »

Visolis Financial Metrics